Nymox Pharmaceutical (NYMX) has been accused of being an outright serial scam by well-known biopharma short expert Richard Pearson. This was from August 10, 2016, and he had this headline for his article - “Nymox: This Offshore 'Biotech' Promotion Will Go To Zero (Yes, Zero).” In that well-written article, he went on to claim how the company hid details of poor trial data from the public, while senior management continued to dump stock without timely SEC disclosure, how the company’s auditor, legal counsel, bankers are all “closely tied to regulatory violations, stock promotions